SYK Stock Recent News

The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and profits, they become more valuable, and investors will be willing to pay more for them.

Stryker Corporation (NYSE:SYK ) Citi's 2025 Unplugged Medtech and Life Sciences Access Day February 27, 2025 12:15 PM ET Company Participants Preston Wells - CFO Jason Beach - VP, Finance, IR Conference Call Participants Joanne Wuensch - Citigroup Joanne Wuensch Joanne Wuensch, the medical technology analyst here at Citi Bank. So for our next session, I'm quite thrilled to have the incoming CFO, Preston Wells and Jason Beach, which I think people know quite well.

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment.

Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy?

Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.

Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025.  Golston joined Stryker's Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees. “We are grateful for Allan's many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We thank Allan for his leadership and dedication in helping Stryker advance our mission of making healthcare better.” Golston has served as the President, United States Program for the Bill & Melinda Gates Founda

Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.

As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.